X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (78) 78
index medicus (77) 77
ritonavir-boosted atazanavir (76) 76
hiv infections - drug therapy (69) 69
pharmacology & pharmacy (47) 47
infectious diseases (46) 46
antiretroviral therapy (44) 44
female (44) 44
male (44) 44
hiv (42) 42
adult (41) 41
middle aged (33) 33
atazanavir (30) 30
atazanavir sulfate (27) 27
protease inhibitors (27) 27
hiv-infected patients (25) 25
tenofovir (25) 25
anti-hiv agents - therapeutic use (24) 24
microbiology (22) 22
pharmacokinetics (20) 20
anti-hiv agents - adverse effects (19) 19
drug therapy, combination (19) 19
efficacy (19) 19
anti-hiv agents - administration & dosage (18) 18
hiv infections - virology (18) 18
hiv protease inhibitors - therapeutic use (18) 18
hiv infection (17) 17
ritonavir (17) 17
tenofovir disoproxil fumarate (17) 17
drug interactions (16) 16
immunology (16) 16
drug therapy (15) 15
infected patients (15) 15
oligopeptides - therapeutic use (15) 15
protease inhibitor (15) 15
pyridines - adverse effects (15) 15
pyridines - therapeutic use (15) 15
hiv protease inhibitors - adverse effects (14) 14
naive hiv-1-infected patients (14) 14
oligopeptides - adverse effects (14) 14
hiv-1-infected patients (13) 13
initial treatment (13) 13
pyridines - administration & dosage (13) 13
safety (13) 13
active antiretroviral therapy (12) 12
double-blind (12) 12
hiv protease inhibitors - pharmacokinetics (12) 12
human immunodeficiency virus--hiv (12) 12
oligopeptides - administration & dosage (12) 12
ritonavir - therapeutic use (12) 12
young adult (12) 12
antiviral agents (11) 11
drug administration schedule (11) 11
efavirenz (11) 11
hiv protease inhibitors - administration & dosage (11) 11
human-immunodeficiency-virus (11) 11
pyridines - pharmacokinetics (11) 11
ritonavir - administration & dosage (11) 11
treatment outcome (11) 11
anti-hiv agents - pharmacokinetics (10) 10
antiretroviral drugs (10) 10
article (10) 10
darunavir (10) 10
dosage and administration (10) 10
glomerular-filtration-rate (10) 10
hiv infections - complications (10) 10
hiv-1 - drug effects (10) 10
oligopeptides - pharmacokinetics (10) 10
risk factors (10) 10
ritonavir-boosted darunavir (10) 10
steady-state pharmacokinetics (10) 10
treatment-naive (10) 10
twice-daily lopinavir/ritonavir (10) 10
aged (9) 9
aids/hiv (9) 9
co-formulated elvitegravir (9) 9
combination (9) 9
drug resistance, viral (9) 9
highly active antiretroviral therapy (9) 9
hiv patients (9) 9
hiv-1 (9) 9
lopinavir/ritonavir (9) 9
medicine & public health (9) 9
pharmacology/toxicology (9) 9
treatment-experienced patients (9) 9
virology (9) 9
virus diseases (9) 9
acquired immune deficiency syndrome--aids (8) 8
anti-retroviral agents - adverse effects (8) 8
hyperbilirubinemia (8) 8
internal medicine (8) 8
lopinavir (8) 8
once-daily atazanavir/ritonavir (8) 8
pharmacotherapy (8) 8
plasma-concentrations (8) 8
proteases (8) 8
raltegravir (8) 8
viral load (8) 8
acute interstitial nephritis (7) 7
anti-retroviral agents - therapeutic use (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, pp. e0123670 - e0123670
Introduction Ritonavir-boosted atazanavir (ATV/r) is a relatively well tolerated antiretroviral drug. However, side effects including hyperbilirubinemia,... 
UNBOOSTED ATAZANAVIR | BILIRUBIN | HYPERBILIRUBINEMIA | EFFICACY | PHARMACOKINETICS | TOLERABILITY | MULTIDISCIPLINARY SCIENCES | ANTIRETROVIRAL THERAPY | RENAL STONES | POLYMORPHISM | RITONAVIR-BOOSTED ATAZANAVIR | Nephrolithiasis - chemically induced | Atazanavir Sulfate - administration & dosage | Humans | Middle Aged | Male | Atazanavir Sulfate - adverse effects | Atazanavir Sulfate - pharmacokinetics | Drug Dosage Calculations | Dyslipidemias - blood | HIV-1 - physiology | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Hyperbilirubinemia - chemically induced | Adult | Female | Hyperbilirubinemia - physiopathology | Nephrolithiasis - physiopathology | Dyslipidemias - diagnosis | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Atazanavir Sulfate - blood | Drug Administration Schedule | Hyperbilirubinemia - diagnosis | HIV-1 - drug effects | HIV Infections - virology | Nephrolithiasis - blood | HIV Protease Inhibitors - administration & dosage | Nephrolithiasis - diagnosis | Antiretroviral Therapy, Highly Active | Hyperbilirubinemia - blood | Dyslipidemias - chemically induced | HIV Infections - drug therapy | Drug Monitoring | Viral Load - drug effects | Dyslipidemias - physiopathology | Highly active antiretroviral therapy | HIV patients | HIV (Viruses) | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Toxicity | Ritonavir | Complications | Dyslipidemia | Lipids | Nephrolithiasis | Dosage | Patients | Side effects | Hyperbilirubinemia | Acquired immune deficiency syndrome--AIDS | Protease inhibitors | Antiretroviral agents | Human immunodeficiency virus--HIV | All terrain vehicles | Index Medicus | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
Drugs, ISSN 0012-6667, 2009, Volume 69, Issue 8, pp. 1107 - 1140
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2010, Volume 54, Issue 12, pp. 5242 - 5250
Journal Article
Drugs, ISSN 0012-6667, 9/2012, Volume 72, Issue 9, pp. 1161 - 1173
Journal Article
Journal of Mass Spectrometry, ISSN 1076-5174, 09/2013, Volume 48, Issue 9, pp. 1019 - 1031
Journal Article
Journal Article
The AAPS Journal, ISSN 1550-7416, 12/2011, Volume 13, Issue 4, pp. 598 - 605
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 3/2017, Volume 34, Issue 3, pp. 619 - 628
Journal Article
PHARMACOGENOMICS, ISSN 1462-2416, 05/2019, Volume 20, Issue 7, pp. 517 - 527
Aim: To evaluate the influence of genetic polymorphisms on plasma trough concentrations of atazanavir (ATV) and ritonavir (RTV). Patients & methods: The... 
GENETIC POLYMORPHISMS | RECEPTOR PXR | CYP3A5 6986A > G | LOPINAVIR | polymorphisms | PROTEASE INHIBITORS | RITONAVIR-BOOSTED ATAZANAVIR | plasma concentrations | UNBOOSTED ATAZANAVIR | ANTIRETROVIRAL DRUGS | IMPACT | PHARMACOKINETICS | atazanavir | PLASMA-CONCENTRATIONS | ritonavir | SLCO1B1 521T > C | PHARMACOLOGY & PHARMACY
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 04/2014, Volume 24, Issue 4, pp. 195 - 203
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 1/2010, Volume 65, Issue 1, pp. 129 - 137
Journal Article